Edition:
United Kingdom

Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig™


Thursday, 28 Jun 2018 

June 28 (Reuters) - Amgen Inc ::AMGEN AND NOVARTIS PRESENT NEW DATA DEMONSTRATING LONG-TERM EFFICACY, SAFETY AND TOLERABILITY OF AIMOVIG™ (ERENUMAB-AOOE) IN PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE.AMGEN - RESULTS FROM A ONE-YEAR STUDY IN CHRONIC MIGRAINE PATIENTS "REINFORCED" ESTABLISHED SAFETY AND EFFICACY PROFILE OF AIMOVIG IN LONG-TERM USE.AMGEN INC - SAFETY RESULTS OF STUDY AFTER ONE YEAR WERE CONSISTENT WITH ESTABLISHED SAFETY PROFILE OF AIMOVIG IN PREVIOUS STUDIES.AMGEN INC - EFFICACY DATA OF STUDY SHOWED SUSTAINED BENEFITS UP TO ONE YEAR.AMGEN INC - AIMOVIG STUDY IS CONTINUING FOR UP TO FIVE YEARS OF TREATMENT.